12 of 14 investments
hg medical
hg medical is a leading end-to-end contract manufacturer of high-quality implants with a particular focus on innovative systems that address lower extremities disorders
Investment year: 2023
Sustainable development goals:
CordenPharma
CordenPharma is a leading CDMO focused on fast-growing complex niche drug modalities with end to end capabilities from early stage development to commercial large-scale manufacturing.
Investment year: 2022
Sustainable development goals:
OPEN Health
OPEN Health is a global leading medical affairs and market access platform serving the pharma industry.
Investment year: 2022
Sustainable development goals:
Avania
Avania is one of the leading global providers of outsourced clinical trial services specifically focused on medical technology, covering the full regulatory lifecycle across a broad range of therapeutic areas.
Investment year: 2022
Sustainable development goals:
Demetra
Demetra is a world-leading player in the bone cement and biomaterials space, serving all the major players in the orthopaedic industry.
Investment year: 2021
Sustainable development goals:
Cytel
Cytel is widely recognized as the industry pioneer of adaptive clinical trials technology and a thought-leader in biostatistical science.
Investment year: 2021
Sustainable development goals:
LGC
LGC's products form an essential part of its customers' quality assurance procedures and enable organisations to develop and commercialise new scientific products and advance research.
Investment year: 2020
Sustainable development goals:
Clario
Clario delivers leading endpoint technology solutions for clinical trials.
Investment year: 2020
Sustainable development goals:
Nemera
Nemera is a world leader in the design, development, and manufacture of drug delivery devices for the pharmaceutical, biotech, and generics industries.
Investment year: 2019
Sustainable development goals:
Echosens
Echosens is a specialized diagnostic company providing non-invasive medical devices and services to support physicians in their diagnostic and monitoring of chronic liver diseases.
Investment year: 2018
Sustainable development goals:
HRA Pharma
HRA is an innovative OTC pharma company with leading positions in Europe and in the US.
Investment year: 2016
Sustainable development goals:
Ethypharm
Founded in 1977, Ethypharm is a European-based specialty pharmaceutical company with global reach and a committed player in the treatment of pain, addiction and critical care.
Investment year: 2007
Healthcare RealisedAstorg in numbers
Years of investment
26
Investments to date
69
Annualized Return
27%